Recent Updates — ICCM
Director Yang Huang notified the company on October 4, 2026, that he will not seek re-election to the board of directors at the upcoming Annual and Special General Meeting of Shareholders scheduled for November 2, 2026. The filing also includes an amended proxy statement seeking shareholder approval for equity-based compensation grants: approximately $1.3 million in Restricted Share Units (RSUs) to CEO Eyal Shamir and a two-tranche grant totaling up to approximately $513,000 plus additional RSUs contingent on financing to Chairman Ron Mayron. The company operates in the medical device industry, developing cryoablation systems for oncology.
The American Medical Association declined to approve IceCure's request to replace the temporary Category III CPT code with a permanent Category I code for treating cancerous breast tumors. The decision follows a September 2026 review and allows the company time to expand clinical evidence and utilization of its ProSense system ahead of a potential resubmission in June 2027. The ruling does not affect existing reimbursement under the temporary code, which pays approximately $4,000 for facility fees via CMS. IceCure Medical Ltd. develops cryoablation technology for oncology treatments.
On September 10, 2026, IceCure Medical Ltd. announced it received approval from China’s National Medical Products Administration (NMPA) to market its ProSense® system and associated cryoprobes as a Class III medical device in China. This regulatory milestone enables the commercialization of the company's flagship cryoablation technology in the Chinese market, expanding its global reach beyond existing approvals in the U.S., Europe, and Asia. IceCure Medical Ltd. develops and markets advanced liquid-nitrogen-based cryoablation therapy systems for the destruction of tumors by freezing.
On August 24, 2026, IceCure Medical Ltd. announced an exclusive distribution agreement with Scovas Medical for its ProSense® cryoablation systems in the Netherlands. The initial term is subject to negotiation of a longer-term agreement. This partnership supports market development and clinical education in a key European market where the independent THERMAC breast cancer trial has advanced to Phase III, highlighting cryoablation's high complete ablation rate. IceCure Medical Ltd. develops minimally-invasive liquid-nitrogen-based cryoablation therapy systems for tumor destruction.